CSIMarket
 

Exicure Inc   (XCUR)
Other Ticker:  
 

Exicure Inc 's

Competitiveness


 

XCUR Sales vs. its Competitors Q2 2023







Revenue Growth Comparisons




Net Income Comparison




<<  XCUR Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Exicure Inc Contracts

Exicure, Inc. and Bluejay Therapeutics Join Forces to Develop Revolutionary Hepatitis C Treatment

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of HepatitisCHICAGO - Exicure, Inc. (NASDAQ:XCUR), a renowned developer of nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company specializing in viral and liver diseases, have recently announced a significant collaboration. The two companies have entered into a patent license agreement with the aim of developing cavrotolimod as a potential treatment for hepatitis.Hepatitis is a prevalent and serious condition affecting millions of individuals worldwide. While several advancements have been made in treating different types of hepatitis...





Who are Exicure Inc 's Competitors?





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com